Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
about
The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic reviewProphylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies.A rapid, simple questionnaire to assess gastrointestinal symptoms after oral ferrous sulphate supplementation.Effect of iron content on the tolerability of prenatal multivitamins in pregnancy.Implications of gender and pregnancy for antiretroviral drug dosingIsoform-specific regulation of cytochrome P450 expression and activity by estradiol in female rats.Designing drug trials: considerations for pregnant women.Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant womenPopulation pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Transplacental Distribution of Lidocaine and Its Metabolite in Peridural Anesthesia Administered to Patients With Gestational Diabetes MellitusPopulation pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancyEnrolling pregnant women: issues in clinical research.Changes in antidepressant metabolism and dosing across pregnancy and early postpartumAltered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymesSex-specific differences in CYP450 isoforms in humans.The second wave: Toward responsible inclusion of pregnant women in researchPhysiologic and pharmacokinetic changes in pregnancy.Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.Antipsychotic use in pregnancy.Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome.Pharmacokinetic studies in pregnant women.Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension.Plasma disposition kinetics of moxidectin after subcutaneous administration to pregnant sheep.Pregnancy and the global disease burden.Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach.Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.Towards an appropriate framework to facilitate responsible inclusion of pregnant women in drug development programs.Drug development for use during pregnancy: impact of the placenta
P2860
Q28079877-E66340BA-95D8-49F3-BB14-951FA1C73431Q30359710-29949117-D0C1-47D7-9EBE-EA72D9B95C38Q31162765-0FB904E8-1117-4FF1-8AFA-D5C1BCFE74F6Q33334978-EDB97B17-9FB2-4C8B-8889-9569B28C8B6BQ33584069-F7DCF325-2047-4B8E-9180-426A51B9ACF6Q34701897-392BD973-6FDD-4C40-9CA7-8A0A3445F8ECQ34999905-C5BB6759-0760-42D7-B46D-62F03451F848Q35547832-B8D2B3EB-21DA-458E-85A6-FAE9DC3B7C58Q35746240-8BA8A93C-419F-4968-82E7-61CD11B187BEQ35867343-9240641C-5188-4E3C-AF04-01EA674FF9FDQ36047153-07CF9E46-4072-454A-8BEC-D352C95A11D8Q36364248-B1DDE1A4-AC62-4CAD-942F-93828E6BC072Q36538758-05675631-388D-4BC7-B795-9966694E3F47Q36541077-B89B1915-AA76-4526-BAF9-128D142D984BQ36692162-48DD4CF6-5037-49C8-A9B7-25E254A44B05Q36939547-5AF590A4-D9D4-4E25-9C1A-7D6B82F3C6B2Q37181876-25D8B738-19B1-485A-9FD0-E72D3AEDDE28Q37354964-F9413415-B4C8-429C-8D86-314463528972Q37695386-FFC76624-EF15-4948-A02B-C2F79116037CQ38215072-930D3A00-AEED-4DA7-9726-9D5B76694FA5Q38498051-436474A0-B7FD-4DC3-9CF4-E05CC2F7A08DQ39754625-38CC454C-F941-4A47-B5B6-1D5B7323E10CQ42007783-890F4BF2-D12D-431E-AFB7-227940A579B7Q44069080-BA17FA7D-85D3-4BC3-9BB9-F911A9BD1AB6Q46260737-299D30DF-6FC3-4D72-B579-1A969111325BQ47145793-AAC0DFC3-AB9F-4E46-85B7-2C4813C77927Q47546991-392C0967-FDEC-49BE-973D-F7EF3FE3CA0EQ47883366-EDBAC82C-851C-453E-B5EE-58DB75127515Q49843269-072B0ECC-62FC-49FC-84A1-A66CB0CEF521Q58392274-412765D3-2A76-4009-B501-04F02F3A6C27
P2860
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@ast
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@en
type
label
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@ast
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@en
prefLabel
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@ast
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@en
P1476
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
@en
P2093
P304
P356
10.1016/S0029-7844(98)00444-X
P407
P433
P577
1999-05-01T00:00:00Z